GlassScriptPhysician profile
Amber Bedley
NPI 1245705425
$2,550.51
in general payments reported to CMS, 2019-2025
24 companies · $734 in 2025
The $734 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $248 · 2022: $296 · 2023: $259 · 2024: $1,014 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.34 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.37 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.43 | 2021-2025 | Xifaxan |
| Genzyme Corporation | $212.83 | 2024-2025 | |
| Intercept Pharmaceuticals, INC. | $164.78 | 2021-2025 | |
| Janssen Biotech, INC. | $159.38 | 2021-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $118.51 | 2024-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $109.74 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $102.56 | 2024-2025 | Voquezna |
| Celgene Corporation | $82.02 | 2021-2024 | Zeposia |
| Pfizer INC. | $80.07 | 2021-2025 | |
| Enterra Medical, INC. | $64.24 | 2025 | |
| Novo Nordisk INC | $57.91 | 2025 | Wegovy |
| Lilly USA, LLC | $41.71 | 2024 | Omvoh |
| Madrigal Pharmaceuticals | $36.32 | 2025 | Rezdiffra |
| Henry Schein, INC. | $33.52 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $31.15 | 2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $29.81 | 2023-2024 | Linzess |
| Daiichi Sankyo INC. | $28.17 | 2022 | |
| Vivus LLC | $21.84 | 2025 | Pancreaze |
| Laborie Medical Technologies Corp. | $21.31 | 2025 | |
| Ardelyx, INC. | $20.31 | 2025 | Ibsrela |
| Organon LLC | $16.67 | 2023 | Renflexis |
| Nestle Healthcare Nutrition INC. | $14.91 | 2023 | |
| Boston Scientific Corporation | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Bedley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.